ArticleFrontiers in stroke2025
Clinico-epidemiological characteristics of cerebral venous sinus thrombosis in Kenya: a retrospective case series.
Article in Frontiers in stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral venous sinus thrombosis (CVST) is a rare cause of stroke that is more common in young, especially female, adults and can be challenging to diagnose due to its frequently non-specific presentation and diverse risk factors. Most cases are idiopathic, and international guidelines do not recommend routine investigations for underlying thrombophilia. Timely diagnosis, with prompt neuroimaging and guideline-based treatment, leads to good outcomes. However, in the literature on CVST from sub-Saharan Africa, the gap is substantial, with the few cases described as being related to systemic and/or brain infections. We describe here the largest cohort of CVST from the region with novel findings that may be relevant to everyday clinical practice. Methods: We conducted a retrospective cross-sectional study of patients diagnosed with CVST from 2010 to 2022 at our tertiary regional neurology referral center in Nairobi, Kenya. Results: We identified 122 cases: 67.2% (82/122) were female, 80.3% (98/122) were Black African, and the median (interquartile range) age was 36.8 (31.5-45.7) years. Apart from headaches (86.9%, 106/122), the most common presenting symptoms were visual disturbance (26.2%, 32/122) and seizures (23.8%, 29/122); 11 patients developed seizures later. Intracranial hemorrhage with and without venous infarction occurred in 27.9% (34/122) of patients. New diagnoses of thrombophilia were made in 30.3% (37/122). Other causes were HIV, hepatitis B/C, or other brain infections (18.0%, 22/118); pregnancy, including postpartum (14.6%, 12/82); contraceptive use (8.5%, 7/82); and malignancy (8.1%, 10/122). The most common treatment was with warfarin in 50% (61/122), followed by rivaroxaban (29.5%, 36/122) and dabigatran [14.8% (18/122)]. Complete thrombus resolution occurred in only 53.9% (55/102) at follow-up scanning (at a median of 178 days). In terms of outcomes (modified Rankin Score [mRS]), 32.8% (40/122) had an mRS score = 0, 59.9% (73/122) had an mRS score = 1-2, and there was one fatality who also had concurrent systemic malignancy. Conclusion: Thrombophilia was more prevalent in our cohort of CVST than infections, which is a novel finding compared to what has been published about CVST from sub-Saharan Africa. Most patients were managed with appropriate anticoagulants, but only about half the patients had complete resolution of the CVST at last follow-up. We therefore recommend that thrombophilia should be routinely investigated in all patients with CVST in our setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.